We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Buy order is there, some sales at 23p bid and then after close 70k buy 23.96p
5000 max buy online and at 24p full offer all these months of waiting is about to pay off here
That 117k I think was a buy because the mm took 100k of sales at mid price and nothing showed to match it but next day they show this trade to make it look like a sale after the rise in price but it matches the sales. Great hint today of good things to come this is going to be a nice winner all we need is patience.....and some volume !
A number of positives in today's RNS's: - Davy coming in as main broker and NOMAD. This is a big step up from Hybridan - a listing on the ESM, which will aid investor interest and liquidity - the CEO's comment that this is "at a time of strong growth and our move into profitability" Http://www.investegate.co.uk/venn-life-sciences--venn-/rns/change-of-adviser/201512110700087348I/
Or was it moved to shift some stock ? The 117K was surely a sell? Shinanigans which ever way.
There has been one being filled for a week mm mopping up all the sales and then larger trades showing later near the full offer price. Stock ran out today for buyers and the price finally started moving. Feel there is a positive trading update coming. Market is devoid of buyers so to see this amount of buying in a usual very quiet stock hints at people in the know
I presume a buy order being filled.
http://www.isdx.com/forcompanies/ourcompanies/companydetail/default.aspx?securityid=1869277 22k 28k and 25k buys all at 21.4p
Buy 22.4p still a overhang but it will clear eventually if people keeping chunking £10k's at it
Of these and they should be trading nearer 30p than 20p and will eventually given the newsflow and strong growth and now they are funded as well. Shame about the fact there is only 2 mm but it should not stop this getting re-rated eventually.
http://tinyurl.com/nqsnktk Tony Richardson, chief executive of Venn Life Sciences (LON:VENN), says the clinical research organisation’s key objective is to pitch for bigger pieces of business resulting in significant multi-million euro contracts. Richardson’s prediction follows the announcement of a €1mln contract from a French biotech. Venn has worked with the unnamed client on a previous clinical trial and Richardson says more large repeat contracts make the delivery of future growth ‘a little easier.’
These are big contracts for a mere £9m m/cap company, but in particular the fact that it's repeat business is very encouraging and a big vindication for the company.
As long as they keep adding contracts then longer term finances look good because of the length of the contracts they win ...... something to think about! All positive, Back to sleep
VENN are still on the lookout for more acquisitions: Http://www.independent.ie/business/irish/richardsons-venn-life-sciences-eyes-eastern-europe-after-buyout-31560000.html "Richardson's Venn Life Sciences eyes Eastern Europe after buyout Irish clinical-research business Venn Life Sciences is eyeing up acquisitions in Eastern Europe after agreeing to buy a Dutch business for up to €6.5m. CEO Tony Richardson, formerly boss of pharmaceutical company Alltracel which was sold for £20.8m in 2008, said the AIM-listed Venn has "talked a lot as a company about getting full European coverage. "At the moment, our locations are all pretty much in Western Europe, so we're looking at Central and Eastern Europe, trying to get some footprint and capability out there and we've had a couple of discussions. They're fairly early-stage, though. "We're looking at one or two other opportunities, nothing hugely developed at the moment." Richardson said Venn's priority after the acquisition of the Dutch business, Kinesis, is to grow by cross-selling the different services within its business. "Combined, we've got a really good client pool to go back to now, with a more complete service offering. "We do clinical trials management in what we call phases two to four. "In summary, that's where you're giving a drug or medication to patients or people who have a particular condition, with a view to hopefully having a submission to a regulator at the end of that process. "Kinesis do everything up to that stage, so if you're a biotech company they would help you to formulate and optimise your compound," he said."
It looks a very good story, with the company building a great business. However DYOR
http://tinyurl.com/nrk654k Tony Richardson, chief executive Venn Life Sciences (LON:VENN), says the company’s acquisition of Dutch drug consultancy Kinesis allows it to pair early and late-stage drug development together. Venn currently offers clinical trial management, monitoring and biometric data services to customers in the later phases of developing treatments. But Kinesis will allow it to supply more early-stage technical services, such as working out how a drug should be administered or how quickly it has worked its way through the body.
that the share price is going backwards again
Excellent stuff: - good H1 results and very confident outlook for a profitable H2 - acquisition at 23p and oversubscribed placing at 22p - Kinesis Pharma already makes historic €0.6m EBITDA so is nicely earnings enhancing No reason why the share price shouldn't continue to advance from here imo. Brief analyst comment amongst other coverage: http://www.proactiveinvestors.co.uk/companies/news/110995/venn-life-sciences-to-offer-one-stop-shop-service-with-kinesis-pharma-deal-110995.html "William Lynne at broker Hybridan said Venn was a good match with Kinesis. He added that half-yearly results were well on track to meet market expectations, with €9m in new contract wins. "Combined with the accretive contribution from Kinesis, the future looks very promising," he said."
acquisition ...... tick tock
Start to the week hopefully it continues
From the July 2015 edition of TechInvest - apologies if already posted " Venn Life Sciences (VENN; AIM) - sp 21p - Venn has secured a €2m contract with a European Biotech company to manage a Phase III study in the area of Rheumatology. The study will involve multiple European countries and will run over a four year period, with most activity occurring during year one. This deal brings the value of new CRO contracts signed so far this year to more than €6m. House broker Zeus Capital commented that, since the Phase III trials are usually the most complicated and extensive, this latest contract underscores the value of Venn’s service offering and geographic coverage. Zeus expects Venn to generate revenues of at least €8.2m for the current year to 31 December with a breakeven bottom line. This compares with €4.9m revenue last year. Venn is showing it is capable of winning complex, higher value contracts. Continue to buy." See http://www.techinvest.ie/ to download a sample copy of the Techinvest Newsletter which contains the above report. It is free to download and contains the above report. I note that VENN is held in the Techinvest Trader Portfolio 4.
Lst 2 reported trades on ISDX are 03/09/2015... 11:08... 50,000... @ 23.85 03/09/2015 ....09:15.. 75,000 ...@ 23.6
always concerns me about placing - but I wonder what they need the cash for? and if not - why have they got them - additional broker coverage?
Latest reported buy 17/08/2015 11:18 41,208 @ 23.9 Max buy currently 15,000 online.
as always , plenty of buying over on isdx with a 40k at 23.3. looking forward to the next piece of news gla